Multicenter preclinical proof-of-concept studies

Pharmahungary Group is offering a unique service in preclinical development, i.e. small and large animal multicenter studies for myocardial infarction and heart failure. The know-how and network of the sites were developed in a COST (EU-CARDIOPROTECTION, CA16225) and COST Innovators Grant (IMPACT, IG16225). Pharmahungary, the SME partner will utilize the know-how of preclinical multicenter trials according to the agreement with the consortium.

 

See selected references:

  • Hernandez-Resendiz S et al, Basic Res Cardiol, 2025 (PMID: 40072549)
  • Kleinbongard P et al, Basic Res Cardiol, 2024 (PMID: 39422732)
  • Lecour S et al, Basic Res Cardiol, 2021 (PMID: 34515837)
  • Sayour NV et al, Cardiovasc Res, 2023 (PMID: 36718529)
Megszakítás